Navigation Links
Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
Date:10/1/2008

reduced abdominal pain and relieved constipation -- the hallmarks of the condition -- throughout the 12-week treatment period. Results from this study will be presented at the American College of Gastroenterology 2008 Annual Scientific Meeting in Orlando, Fla. on October 7, 2008. Positive results from a linaclotide Phase 2b study in 310 patients with CC were detailed in May 2008 at the Digestive Disease Week conference in San Diego. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea.

Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. In preclinical testing, linaclotide was shown to decrease visceral pain, increase fluid secretion into the intestine, and accelerate intestinal transit. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion annually. IBS patients fall largely into three subgroups -- constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed IBS (IBS-M) -- and 30% to 40% of these patients suffer from IBS-C. There are currently few available therapies to treat the nine million U.S. patients diagnosed with IBS-C.

About Chronic Constipation (CC)

As many as 26 million Americans suffer from CC.
'/>"/>

SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
2. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
3. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
4. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Romark Laboratories Raises $18 Million in Institutional Financing
7. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
8. EntreMed Raises $20 Million to Support Clinical Development Program
9. Globus Medical Raises $110 Million in Series E Financing Round
10. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
11. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Warner Chilcott plc (Nasdaq: ... Warner Chilcott Corporation (the "Company") has commenced a ... to the conditions set forth in the Company,s ... December 15, 2009 (the "Offer to Purchase"), for ... subordinated notes due 2015 (the "Notes"). ,, The ...
(Date:12/15/2009)... -- Immucor, Inc. (Nasdaq: BLUD ), a global ... transfusion industry, today announced that it will release its ... 2010 after the market close. The Company will host ... 8:30 a.m. (Eastern Time) to discuss the results. ... conference call by dialing 1-888-324-9321 (Passcode: BLUD). Investors can ...
(Date:12/15/2009)... INCLINE VILLAGE, Nev., Dec. 15 PDL BioPharma, ... it has paid the December 15, 2009 special dividend ... shares of PDL as of December 1, 2009. ... ended December 31, 2009 total $2.67 per share. ... regarding the federal tax characteristics of the Company,s 2009 ...
Breaking Medicine Technology:Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 2Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 3Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 6PDL BioPharma Completes December 15 Special Dividend Payment 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 1ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 2ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 3ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 4ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 5ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 6ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 7ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 8ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 9ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results 13955 10Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 1Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 2Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 3Verenium 1 3A12 Reverse Stock Split Takes Effect 13953 4Brain Scans Could Help Spot Schizophrenia Earlier 56674 1Brain Scans Could Help Spot Schizophrenia Earlier 56674 2
... /PRNewswire-FirstCall/ --,Alfacell Corporation's ONCONASE (ranpirnase) has shown ... antibody conjugates for cancer therapy,according to the ... , In a chapter of the text ... research indicating that the,specificity and potency of ...
... Levels in Two Most Common Mutations, CRANBURY, ... a biopharmaceutical company developing small,molecule, orally-administered pharmacological ... human genetic diseases, announced today,that it will ... (isofagomine tartrate, AT2101) for Gaucher disease at,the ...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:12/15/2009)... released some sobering statistics concerning the parallel rise in diabetes and ... effective means of combating this trend afflicting their workforce. , ... ... diabetes are climbing across America due in large part to the ... Diabetes Association has stated that the rate of diabetes could be ...
(Date:12/15/2009)... to be leaders in the fight against malaria ... experts in online learning, the Masie Center and ... -- ONE and Malaria No More ... first-ever "Malaria Griots" program, a dynamic education course ... leaders in the fight against malaria. ,, ...
(Date:12/15/2009)... 15 4R Systems, Inc., a leading ... which help retailers significantly increase profits by optimizing ... today that The Vitamin Shoppe has been utilizing ... store and DC inventory solutions have helped us ... in-stocks over the last two years," said Tony ...
(Date:12/15/2009)... Patient advocate Betsy McCaughey, Ph.D., will ... "it doesn,t matter whether there,s a public option. The ... option - give government authority over how your doctor ... social agenda by shifting billions of dollars from Medicare ... and local politicians." ,, Betsy McCaughey is ...
(Date:12/15/2009)... CITY, Dec. 15 The new compact LifeSpan ... ( www.LifeSpanFitness.com ), was highly praised by ... treadmills for 2010. The compact TR200 folding treadmill received ... Best Treadmill under $1000. ,, The compact LifeSpan ... in small workout spaces. "This category buster is a ...
Breaking Medicine News(10 mins):Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2
... been proposed by Pharmac, to hold a meeting regarding extension ... the provision of drug to women with early breast cancer. ... advanced breast cancer. Extension of the budget for the cancer ... planned. , ,The company officials are much more ...
... the available treatment methods, it is the socioeconomic status ... cancer, according// to a new study published in the ... of the American Cancer Society. ,The study found ... equally important role in determining the outcomes as did ...
... promoted by India's pharma major Ranbaxy Laboratories, Monday announced the ... can give results in just a day. ,"A first ... bird flu that can be effectively employed for mass screening ... to ten days, which other available tests take," said SRL ...
... a public display of their affection here on Valentine's Day ... by some young lovers. ,Youngsters have got over the ... on lovers by the Akhil Bharatiya Vidhyarthi Parishad (ABVP), the ... ,The move is now being welcomed by courting couples, who ...
... to donate nearly 100 acres of land to guru Baba ... has also been invited to set up a facility for ... state reserve of medicinal plants. ,The government is ... next week when he arrives here for a yoga camp ...
... urged that people restrict their telephonic conversations to a minimal ... phones. ,Germany's federal bureau for radiation protection (BfS) ... to put the base station in an area of their ... The foyer or entrance is a good example. ,The ...
Other Medicine News:
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
... Nile Virus IgG DxSelect is intended,for ... Nile virus in human,serum. In conjunction ... Virus,IgM Capture DxSelect, the test is ... meningioencephalitis, as an aid in the,presumptive ...
... PachPen uses state-of-the-art waveform analysis ... at a 65MHz rate to ... stores and averages nine measurements ... pen fits comfortably into the ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Medicine Products: